As of the data cutoff (18 November 2023), the cORR was 80.0% in Cohort 1 (HER2+ mBC), 23.1% in Cohort 2 (HER2-low mBC), 54.5% in Cohort 3 (HER2e NSCLC), and 66.7% in Cohort 4 (HER2m NSCLC). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.